

Supplementary Table S2. Antibiotics administered to study patients before starting amikacin liposome inhalation suspension

Patient*	Antibiotics and duration, mo									
	Macrolide [†]	Ethambutol	Rifamycin	Moxifloxacin	Linezolid	Clofazimine	Amikacin, intravenous	Amikacin inhalation, non-liposomal		
1	Yes 37.4	Yes 36.5	Yes 37.4	- -	- -	- -	Yes 8.1	- -		
2	Yes 52.9	Yes 35.8	Yes 20.4	Yes 1.8	Yes 1.1	Yes 22.6	Yes 2.4	- -		
3	Yes 23.0	Yes 28.0	Yes 17.0	Yes 0.9	Yes 10.1	Yes 11.0	Yes 5.0	- -		
4	Yes	Yes	-	Yes	Yes	Yes	Yes	Yes (500 mg, three times/week)		
5	Yes 10.3	Yes 10.3	Yes 8.5	- -	4.0 -	20.2 1.8	18.0 -	20.5 -		
6	Yes 55.8	Yes 55.8	Yes 55.8	- -	- -	Yes 2.3	- -	- -		
Overall duration, mo	43.5 (26.6–52.1)	33.2 (28.6–36.3)	20.4 (17.0–37.4)	1.4 (1.1–1.6)	4.0 (2.6–7.0)	20.2 (2.3–20.2)	11.0 (4.3–10.6)	6.6 20.5		

Values are presented as median (interquartile range).

*Patient no. 1, 2, and 5 had *Mycobacterium avium*-disease; no. 3 and 4 had *Mycobacterium intracellulare*-disease. Patient no. 6 had co-infection with *M. avium* and *M. intracellulare*.

[†]Azithromycin or clarithromycin.

-: negative.